Drug Search Results
More Filters [+]

4D-125

Alternative Names: 4D-125, 4D125
Latest Update: 2024-05-06
Latest Update Note: News Article

Product Description

4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04517149)

Mechanisms of Action: Gene Therapy,RPGR

Novel Mechanism: Yes

Modality: Gene Therapy

Route of Administration: Injection

FDA Designation: Fast Track - Retinitis Pigmentosa|Retinitis *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: 4D Molecular
Company Location: EMERYVILLE CA 94608
Company CEO: David Kirn
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for 4D-125

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Retinitis Pigmentosa

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

XLRP

P2

Active, not recruiting

Retinitis Pigmentosa

2026-06-01

24%

Recent News Events